Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
What is an Experiment?01:12

What is an Experiment?

An experiment is a planned activity carried out under controlled conditions. The purpose of an experiment is to investigate the relationship between two variables. When one variable causes change in another, we call the first variable the explanatory or independent variable. The affected variable is called the response or dependent variable. In a randomized experiment, the researcher manipulates values of the explanatory variable and measures the resulting changes in the response variable. The...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Migration and its impact on universal HIV testing and treatment in the HPTN 071 (PopART) study communities.

PLOS global public health·2026
Same author

Feasibility and Acceptability of Barbershop-Based HIV Prevention Among Heterosexual Men in Kalangala Islands, Uganda: Protocol for a Cluster Randomized Trial (HPTN 111).

JMIR research protocols·2026
Same author

High prevalence and incidence of curable sexually transmitted infections among young women using oral HIV pre-exposure prophylaxis in sub-Saharan Africa: results from the INSIGHT Cohort study.

Sexually transmitted infections·2025
Same author

Identifying priority populations for HIV interventions using acquisition and transmission indicators: a combined analysis of 15 mathematical models from ten African countries.

The lancet. HIV·2025
Same author

Awareness of drug supply changes and uptake of fentanyl testing services among people who use drugs in Kampala, Uganda.

Drug and alcohol dependence·2025
Same author

Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083.

The Journal of infectious diseases·2025

Related Experiment Video

Updated: May 10, 2026

A Method to Test the Efficacy of Handwashing for the Removal of Emerging Infectious Pathogens
09:02

A Method to Test the Efficacy of Handwashing for the Removal of Emerging Infectious Pathogens

Published on: June 7, 2017

Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.

Deborah Donnell1, James P Hughes, Lei Wang

  • 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. deborah@fhcrc.org

Journal of Acquired Immune Deficiency Syndromes (1999)
|June 15, 2013
PubMed
Summary

Designing new HIV pre-exposure prophylaxis (PrEP) trials is complex after FTC/TDF approval. New efficacy trials require careful design, considering adherence and ethical issues for effective HIV prevention.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture
11:14

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture

Published on: October 12, 2018

Related Experiment Videos

Last Updated: May 10, 2026

A Method to Test the Efficacy of Handwashing for the Removal of Emerging Infectious Pathogens
09:02

A Method to Test the Efficacy of Handwashing for the Removal of Emerging Infectious Pathogens

Published on: June 7, 2017

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture
11:14

Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture

Published on: October 12, 2018

Area of Science:

  • HIV Prevention Research
  • Clinical Trial Design
  • Pharmacology

Background:

  • Systemic pre-exposure prophylaxis (PrEP) development faces challenges post-FDA approval of emtricitabine/tenofovir (FTC/TDF).
  • Inconsistent efficacy results from FTC/TDF PrEP trials complicate the development of new interventions.

Purpose of the Study:

  • To explore potential designs for Phase 3 efficacy trials of new PrEP regimens.
  • To evaluate scenarios involving experimental PrEP, control regimens, and dosing strategies.

Main Methods:

  • Consideration of noninferiority (NI) and superiority trial designs.
  • Analysis of NI margins (1.10-1.25) justified by existing FTC/TDF efficacy data.
  • Evaluation of trial feasibility based on participant numbers and adherence challenges.

Main Results:

  • NI trials may require large participant numbers, especially where FTC/TDF is effective.
  • NI trials are challenging to interpret due to reliance on prior placebo-controlled data.
  • Superiority trials are viable for new PrEP in settings with low FTC/TDF adherence.

Conclusions:

  • New PrEP efficacy trials need stringent design standards post-FTC/TDF approval.
  • Rigorous discussion of adherence and ethical considerations is crucial for trial success.
  • Careful trial design is essential for advancing HIV prevention strategies.